Inactivated Vaccines Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

What combination of drivers is leading to accelerated growth in the inactivated vaccines market?
As the incidence of infectious illnesses continues to rise, the inactivated vaccine market is projected to experience significant growth. Infectious diseases, which can be transmitted from one person to another and can result in a variety of symptoms and health issues, are caused by various pathogens, including bacteria, viruses, fungi, and parasites. Tuberculosis is one such infectious disease. Inactivated vaccines, which utilize non-living pathogens to trigger an immune response, play a crucial role in preventing diseases like polio, hepatitis A, and influenza. For instance, data published by the Centers for Disease Control and Prevention in November 2023 revealed that the count of tuberculosis patients in the USA rose from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Hence, the growing incidence of infectious diseases is pushing the inactivated vaccine market's growth forward. The upswing in immunization initiatives is also anticipated to fuel the growth of the inactivated vaccines market in the upcoming period. Immunization efforts or initiatives typically involve coordinated campaigns to vaccinate individuals or communities against specific diseases. These initiatives are integral to the inactivated vaccines market, prompting an increased demand for these vaccines, stimulating the market growth, and propelling R&D investments. For instance, as per the World Health Organization's data from July 2023, vaccination annually prevents a loss of 4-5 million lives globally, offering protection against infectious diseases like hepatitis, diphtheria, tetanus, whooping cough, measles, and polio. It added that in 2022, nearly 84% of infants worldwide received three doses of the polio vaccine. The same year, an estimated 84% of infants in countries using oral polio vaccines also got their first dose of the inactivated polio vaccine. Consequently, these increasing immunization initiatives are accelerating the growth of the inactivated vaccines market.

Get Your Inactivated Vaccines Market Report Here:
https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

What is the projected compound annual growth rate (CAGR) of the inactivated vaccines market from 2025 to 2034, and what factors influence it?
The market space for inactivated vaccines has witnessed consistent expansion in recent years. The market size is projected to increase from $6.19 billion in 2024 to $6.44 billion in 2025, boasting a compound annual growth rate (CAGR) of 4.0%. This growth during the historic period can be credited to efforts to eradicate polio, influenza vaccination initiatives, the emergence of new infectious diseases, and regulatory approvals.

The market size of inactivated vaccines is anticipated to experience consistent growth in the upcoming years. The market is projected to reach a value of $7.75 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.7%. This projected growth during the forecast period is due to factors such as response preparation for pandemics, enhanced vaccine coverage, advancements in biomanufacturing, and initiatives related to health equity. The major expected trends during the prediction period include mRNA vaccine platforms, combination vaccines, thermostable vaccines, and the introduction of digital vaccine passports.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

How are the latest trends influencing the growth of the inactivated vaccines market?
Leading firms in the inactivated vaccines market are consistently developing new and upgraded inactivated vaccines as a strategy to maintain their market standing. These vaccines are created with inactivated virus particles, bacteria, or other pathogens cultivated in a controlled environment and subsequently killed to eliminate their capacity to cause disease. For example, in January 2022, UK's pharmaceutical and biotechnology company, GSK PLC, launched Shingrix, a novel inactivated vaccine for shingles protection. Shingrix, an adjuvanted non-live, recombinant subunit vaccine, is administered via two intramuscular doses. Originally, this vaccine was intended for individuals aged 50 and above. However, it has recently been made available to those aged 18 and above with a higher risk of shingles due to immunosuppression or immunodeficiency from a known disease or therapy.

What are the major segments of the inactivated vaccines market and their role in driving growth?
The inactivated vaccines market covered in this report is segmented -

1) By Type: Viral Vaccine, Bacterial Vaccine
2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:
1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine
2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13018

Which regions are key players in the growth of the inactivated vaccines market?
North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the key firms paving the way for growth in the inactivated vaccines market?
Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

What Is Covered In The Inactivated Vaccines Global Market Report?

•Market Size Forecast: Examine the inactivated vaccines market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the inactivated vaccines market for a structured understanding.
•Key Players Overview: Analyze major players in the inactivated vaccines market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the inactivated vaccines market.
•Segment Contributions: Evaluate how different segments drive overall growth in the inactivated vaccines market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the inactivated vaccines market.
•Industry Challenges: Identify potential risks and obstacles affecting the inactivated vaccines market.
•Competitive Landscape: Review strategic developments in the inactivated vaccines market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.